

DAFTAR PUSTAKA

- Anthony, L., 2013. Junquera's Basic Histology. 13th edition, Washington, Lange: 818.
- Bandarchi, B., Ma, L., Navab, R, Seth, A., Rasty, G., 2010. From melanocyte to metastatic malignant melanoma. Hindawi Publ Corp Dermatology Research and Practice, 1-5.
- Bucheit, A.D., Syklawer, E., Jakob, J.A., Bassett, J.R.L., Curry, J.L., Gershenwald, J.E., Kim, K.B., Hwu, P., Lazar, A.J, Davies, M.A., 2013. Clinical characteristics and outcomes with specific BRAF and NRAS mutations in patients with metastatic melanoma. *Cancer*, 119, 3821–3829.
- Dickson, P.V., Gershenwald, J.E., 2011. Staging and prognosis of cutaneous melanoma. *Surg Oncol Clin N Am*, 20, 1-17.
- Edmund, K., Bartlett, M.D., Giorgos, C., Karakousis, M.D., 2015. Current Staging and Prognosti Factors in Melanoma. *Surg Oncol Clin N Am*, 24, 215–227.
- Ehsani, L., Cohen, C., Fisher, K.E., Siddiqui, M.T., 2014. BRAF mutations in metastatic malignant melanoma: comparison of molecular analysis and immunohistochemical expression. *Appl Immunohistochem Mol Morphol*, 22(9),648-51.
- Hermin Aminah Usman, Bethy S Hernowo, Maringan Diapari Lumban Tobing, Reti Hindritiani. 2018. Result Analysis of BRAF V600E Gene Mutation Using Molecular and Immunohistochemistry Detection in Acral Malignant Melanoma. *Asian Pac J Cancer Care*, 3 (3), 43-45.
- Hugdahl, E., Kalvenes, M.B., Puntervoll, H.E., Ladstein, G., Akslén, L.A., 2016. BRAF-V600E expression in primary nodular melanoma is associated with aggressive tumour features and reduced survival. *Br J Cancer*, 114, 801-8.
- Humphrey, P.A., Dehner, L.P., Pfeifer, J.D., 2008. Skin: melanocytic lesions/melanoma. In: LIND, A. C., BANTLE, E. A., DEHNER, L. P., eds. *The Washington Manual of Surgical Pathology*. Philadelphia: Lippincott Williams & Wilkins, 503.
- James, William, D., Berger, Timothy, G., 2006. *Andrews' Diseases of the Skin: clinical Dermatology*. Saunders Elsevier.
- Jonathan, B., Heistein, Utkarsh, Acharya, 2019. *Cancer, Malignant Melanoma*. StatPearls Publishing.
- Jürgen, Bauer, Nicholas, A., Kolaitis, Petra B., Rajmohan, M., Ichiro, O., Maria T. L., Richard, A., Scolyer, Boris, C., 2011. Bastian. BRAF mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumor and the degree of solar elastosis at the primary tumor site. *Pigment Cell Melanoma Res*, 24, 345–351.
- Justine, S., Eric W., Melanoma, Available from <http://www.pathophys.org/melanoma>.
- Kyung, W.Nam., Yong C.B., Soo B. N., Joo H.K., Hoon S.K., Young J.C., 2016. Characteristics and Treatment of Cutaneous Melanoma of the Foot. *Arch Plast Surg* 2016;43:59-65

- Lee, H.Y., Chay, W.Y., Tang, M.B., Chio, M.T., Tan, S.H., 2012. Melanoma: differences between Asian and Caucasian patients. *Ann Acad Med Singapore*, 41, 17-20.
- Liu. Y.M., Saeed, S., 2015. Melanoma: Molecular Pathogenesis and Therapeutic Management. *Mol Cell Pharmacol*, 6(3), 228.
- Long, G.V., Menzies, A.M., Nagrial, A.M., Haydu, L.E., Hamilton, A.L., Mann, G.J., Hughes, T.M., Thompson, J.F., Scolyer, R.A., Kefford, R.F., 2011. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. *J Clin Oncol*, 29, 1239–1246.
- Muñoz, E., García, J., Pérez J., Cebrián, V., Castán, J., 2015. Recent advances in the treatment of melanoma with BRAF and MEK inhibitors. *Ann Transl Med*, 3(15), 207.
- Oliver, J., Wisco, D., 2012. Prognostic Factors for Melanoma. *Dermatol Clin* 30 469–485
- Paek, S., Sober, A., Tsao, H., Mihm, M., Johnson, T.M., 2008. Cutaneous melanoma Fitzpatrick's dermatology in general medicine. 7th ed, 1134-57.
- Paolo Ascierto, John Kirkwood, Jean-Jacques Grob, Ester Simeone, Antonio M Grimaldi, Michele Maio, Giuseppe Palmieri, Alessandro Testori, Francesco Marincola, Nicola Mozzillo., 2012. The role of BRAF V600 mutation in melanoma. *Journal of Translational Medicine*, 10:85.
- Ross, M.H., 1985. *Histology, A Text And Atlas*, New York, Harper & Row 1985:416-23
- Sangeetha, R., Dirk S., Georgina, 2015. Systemic therapies for melanoma brain metastases: which drug for whom and when?. *Chin Clin Oncol*, 4(2):25
- Smoller, 2006. Histologic criteria for diagnosing primary cutaneous malignant melanoma. *Modern Pathology*, 19, S34–S40.
- Smalley, K.S., 2003. A pivotal role for ERK in the oncogenic behaviour of malignant melanoma? *Int J Cancer*, 104, 527–532.
- Spagnolo, F., Queirolo, P., 2012. Upcoming strategies for the treatment of metastatic melanoma. *Arch Dermatol Res*, 304, 177–184.
- Sujeet, K., 2015. Normal Skin Histology. Available from <https://undergraduatepathologydotcom.wordpress.com>
- Yi-Shuan, Sheen., Ming-Hsien, L., Yi-Hua, L., Jau-Yu L., Chia-Yu, C., Yi-Chun, H., Shiou-Hwa, J., 2016. Prevalence of BRAF and NRAS mutations in cutaneous melanoma patients in Taiwan. *Journal of the Formosan Medical Association*, 115, 121-127.
- Zoe. A., Aimilios, L., Elena, S., Elizabeth, L., Demetrios, I., 2017. Epidemiological trends in skin cancer. *Dermatol Pract Concept*.7(2):1

